Tag Archives | cannabinoid drugs

Biotechs Stalled and Get No Help From Monday’s Market Moves…Updates

Updates: 4/19/18 GWPH hits $143 new high,  then sold off holding $134 level, after big move from $105 on cannabis drug for severe epilepsy FDA Advisory go ahead. Biotechs broadly in the red except CRSP up 6.4% and NVCR up 5%. AstraZeneca (AZN) gained US approval for 1st line use of lung cancer drug. Novartis (NVS) shares […]

Continue Reading 0

Rayno Biobeat #1… Hot Biotech Stocks: Searching for Clues in a Chaotic Market

Rayno Life Science… Special Report #1: Hot Biotech Stocks in 2016 Biotech stocks have been in a funk for most of 2016 and then got absolutely crushed in October. The underlying causes are well-known among them bad news from bad actors like Mylan and  Turing, the populist revolt against high drug prices and lackluster top […]

Continue Reading 0

Biotech Bear Market Looking For Relief From Q3 Large Cap Growth…Update-3

Update-3… 10/28 9:30 am… No Relief From Earnings- Biotech Stocks Get Crushed By More Pricing Commentary on Earnings Calls Amgen (AMGN) down 11% on pipeline, revenue growth, Enbrel pricing concerns despite beat. Softer pricing environment from McKesson (MCK). All large caps are red except Alexion (ALXN) up 1.83%. Abbvie (ABBV) down 6% on revenue miss;Humira […]

Continue Reading 0

Biotechs Eke Out Gains On Product Pipeline News…Update-2

Update-2…Market rallies Monday after 2% sell-off on Friday IBB held support at $280, up 1.9% today to 284 as of mid-morning . Mid-caps and large caps strong. —— Update-1… FED Rate Increase Fear Sparks Sell-Off NASDAQ down 1.14%, 10 Year Bond 1.67%, IBB down 1.4%, XBI down 1.64%… 11:30 am EDT. European bonds are also in a […]

Continue Reading 0

Monday Movers in the Biotech Bear Market…ALNY, GILD, GWPH

Tuesday 12:45pm EDT Update on a red screen day: Healthcare sector lags down 1.6%, biotechs now being crushed IBB down 3.1%,XBI down 5%! ——– Look for Value +Growth Picks in a Biotech Bear Market Marijuana Strengthens Clinical Status Review our assumptions from previous posts: Biotech remains in a bear market so sector plays may not […]

Continue Reading 0